Douglas Earl Martin, SVP and General Counsel at Allogene Therapeutics ($ALLO), sold shares once on the open market in the last year, totaling $40,304. His most recent sale occurred on February 2, 2026. These sales rank 10,599th among 11,678 insiders in our database, where the average is $8.6 million across about 6.4 transactions per insider. Martin made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 2, 2026 | Allogene Therapeutics, Inc. | $ALLO | Douglas Earl Martin | SVP, General Counsel | S | Common Stock | 22900 | $1.76 | 564,948.0000 | 224,730,144 | 3.90% | 0.01% |
| Feb. 2, 2026 | Allogene Therapeutics, Inc. | $ALLO | Douglas Earl Martin | SVP, General Counsel | A | Restricted Stock Unit | 152480 | $0.00 | 152,480.0000 | 224,730,144 | 9999.99% | 0.07% |
| Feb. 2, 2026 | Allogene Therapeutics, Inc. | $ALLO | Douglas Earl Martin | SVP, General Counsel | A | Stock Option (Right to buy) | 539072 | $0.00 | 539,072.0000 | 224,730,144 | 9999.99% | 0.24% |
| Feb. 3, 2025 | Allogene Therapeutics, Inc. | $ALLO | Douglas Earl Martin | SVP, General Counsel | S | Common Stock | 6404 | $1.71 | 587,848.0000 | 0 | 1.08% | 0.00% |
| Jan. 24, 2025 | Allogene Therapeutics, Inc. | $ALLO | Douglas Earl Martin | SVP, General Counsel | A | Stock Option (Right to buy) | 512370 | $0.00 | 512,370.0000 | 0 | 9999.99% | 0.00% |
| Jan. 24, 2025 | Allogene Therapeutics, Inc. | $ALLO | Douglas Earl Martin | SVP, General Counsel | A | Common Stock | 144928 | $0.00 | 594,252.0000 | 0 | 32.25% | 0.00% |
| Aug. 21, 2024 | Allogene Therapeutics, Inc. | $ALLO | Douglas Earl Martin | SVP, General Counsel | F | Common Stock | 28310 | $2.79 | 449,324.0000 | 0 | 5.93% | 0.00% |
| Jan. 25, 2024 | Allogene Therapeutics, Inc. | $ALLO | Douglas Earl Martin | SVP, General Counsel | A | Common Stock | 41800 | $0.00 | 477,634.0000 | 0 | 9.59% | 0.00% |
| Jan. 25, 2024 | Allogene Therapeutics, Inc. | $ALLO | Douglas Earl Martin | SVP, General Counsel | A | Stock Option (Right to buy) | 147778 | $0.00 | 147,778.0000 | 0 | 9999.99% | 0.00% |
| Aug. 14, 2023 | Allogene Therapeutics, Inc. | $ALLO | Douglas Earl Martin | GENERAL COUNSEL | A | Stock Option (Right to Buy) | 960854 | $0.00 | 960,854.0000 | 0 | 9999.99% | 0.00% |
| Aug. 14, 2023 | Allogene Therapeutics, Inc. | $ALLO | Douglas Earl Martin | GENERAL COUNSEL | A | Common Stock | 326876 | $0.00 | 435,834.0000 | 0 | 300.00% | 0.00% |
| Aug. 14, 2023 | Allogene Therapeutics, Inc. | $ALLO | Douglas Earl Martin | GENERAL COUNSEL | A | Common Stock | 108958 | $0.00 | 108,958.0000 | 0 | 9999.99% | 0.00% |